Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
about
Tumor stroma as targets for cancer therapyCCL18 in a multiplex urine-based assay for the detection of bladder cancerCombined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patientsMelanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzymeFunctional protease profiling for diagnosis of malignant disease.Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.Prognostic factors of second primary contralateral breast cancer in early-stage breast cancer.Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasisuPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.Metastasis of ovarian cancer is mediated by kallikrein related peptidases.Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Impact of expression of the uPA system in sarcomas.Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.Precision treatment for cancer: role of prognostic and predictive markers.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Inhibition of uPAR-TGFβ crosstalk blocks MSC-dependent EMT in melanoma cells.Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase Cascades.An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas.uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer.Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
P2860
Q27015980-938ACFD0-4395-46E8-B479-32090607996BQ28729838-B2DC1205-EA71-404A-8415-AEA127AABB4EQ31021361-1E22E184-420F-4C6C-B9AC-ADC898340182Q33977030-BD8B0C42-1718-4A35-A769-B4CB70C93559Q34116114-D0E867C7-0CDD-4A5E-978A-C66D3C677F25Q34434875-9AC2D229-0FFA-4516-B346-592709FB28DAQ34582515-E825FB5A-5346-4DA2-B8F2-E9BBEB7243D4Q34995476-E133E49C-5EF2-4775-BD68-301990C3E9DBQ35580701-3EBFC280-29A2-4BCA-B743-0889B7FFAFA8Q36037989-DBDFFE12-9A8A-4A74-916B-216DE380FF5DQ36386574-CFF74287-0A05-4EE0-844A-3FDAA994D65AQ37480184-73AC8548-B6F3-44D4-8321-0E791FD0C872Q37899888-EC385B52-BD7D-4090-93AD-2D4416B00F68Q38111811-23BCFC08-E8A0-4F90-9A62-9A39775E9D12Q38120755-15DC35FC-EF76-4651-A663-92D52B7B6636Q38179024-A74F9F0A-1A1F-4F45-8B01-49ECF5751B1DQ38184632-D54BC86B-28EA-4E68-A1FA-C05A2AF0D8EDQ38908272-4884C275-1B64-4067-BF28-0679E8075E12Q39115394-E9B1F2F7-4E11-44B7-BE04-1927413D6494Q39480395-9E4504B4-37A4-4FEE-987C-F9228DCA68C6Q39644934-CF23E476-B12C-49EB-87E2-90864D1082F4Q41808886-2BF5729E-5D41-420F-9653-8202BCF6971EQ41905619-995081A7-7F52-4970-AB3D-786E9D9D5247Q42508717-3FBDC1B3-05BA-46C5-A99A-8E494FB8DBF5Q43797297-A944CD2E-045C-4B61-A97A-6A5160F3386BQ43997799-41735330-7C96-4C9E-A860-8FE6720B1E3EQ48333132-AEA011FC-23E0-4908-B882-C7FF36648DACQ50014444-E121031C-C633-4C2C-9804-BC56DD8E2BD2
P2860
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Clinical utility of level-of-e ...... s uPA and its inhibitor PAI-1.
@en
Clinical utility of level-of-e ...... s uPA and its inhibitor PAI-1.
@nl
type
label
Clinical utility of level-of-e ...... s uPA and its inhibitor PAI-1.
@en
Clinical utility of level-of-e ...... s uPA and its inhibitor PAI-1.
@nl
prefLabel
Clinical utility of level-of-e ...... s uPA and its inhibitor PAI-1.
@en
Clinical utility of level-of-e ...... s uPA and its inhibitor PAI-1.
@nl
P2093
P2860
P356
P1476
Clinical utility of level-of-e ...... s uPA and its inhibitor PAI-1.
@en
P2093
Apostolos Gkazepis
John Foekens
Karin Mengele
Manfred Schmitt
Nils Brünner
Rudolf Napieralski
Ute Reuning
Viktor Magdolen
P2860
P304
P356
10.1586/ERM.10.71
P577
2010-11-01T00:00:00Z